Does Exposure and Response Prevention Behaviorally Activate Patients With Obsessive-Compulsive Disorder? A Preliminary Test.


Journal

Behavior therapy
ISSN: 1878-1888
Titre abrégé: Behav Ther
Pays: England
ID NLM: 1251640

Informations de publication

Date de publication:
01 2019
Historique:
received: 06 09 2017
revised: 22 05 2018
accepted: 25 05 2018
entrez: 22 1 2019
pubmed: 22 1 2019
medline: 2 5 2019
Statut: ppublish

Résumé

Exposure and response prevention (ERP) and behavioral activation (BA) are effective treatments for obsessive-compulsive disorder (OCD) and depression, respectively. Patients with OCD often exhibit depression; furthermore, ERP for OCD is associated with reduced depressive symptoms. To our knowledge, no study has examined whether ERP itself functions to behaviorally activate patients with concurrent OCD and depressive symptoms. This prospective study was designed to test the hypotheses that (a) OCD exposure hierarchy completion, increased BA, and depressive symptom reduction would all be related, and (b) pre- to posttreatment changes in BA would mediate the direct effect of OCD hierarchy completion on posttreatment depressive symptoms, even after controlling for pretreatment depressive symptoms, pretreatment BA, pre- to posttreatment reductions in OCD symptoms, treatment duration, and antidepressant medication use. Patients (N = 90) with a primary diagnosis of OCD who received residential ERP for OCD completed a self-report battery at pre- and posttreatment. Exposure hierarchy completion, increases in BA, and decreases in depression were all significantly correlated (rs ranged .33 to .44). The effect of hierarchy completion on posttreatment depressive symptoms was fully mediated by pre- to posttreatment changes in BA. Findings highlight the potential for ERP to exert antidepressant effects by behaviorally activating patients. Limitations, clinical implications, and future directions are discussed.

Identifiants

pubmed: 30661561
pii: S0005-7894(18)30066-2
doi: 10.1016/j.beth.2018.05.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-224

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

Shannon M Blakey (SM)

University of North Carolina at Chapel Hill.

Jonathan S Abramowitz (JS)

University of North Carolina at Chapel Hill. Electronic address: jabramowitz@unc.edu.

Rachel C Leonard (RC)

Rogers Memorial Hospital.

Bradley C Riemann (BC)

Rogers Memorial Hospital.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH